0
     

Report Added
Report already added
Genomic Biomarkers Market: Segmented: By Type (Oncology, Cardiovascular diseases, Neurological diseases, Renal Disorders and Others); By End user (Hospitals, Diagnostic centre and Others), And Region – Global Analysis of Market Size, Share & Trends For 2019–2020 And Forecasts To 2031

Genomic Biomarkers Market: Segmented: By Type (Oncology, Cardiovascular diseases, Neurological diseases, Renal Disorders and Others); By End user (Hospitals, Diagnostic centre and Others), And Region – Global Analysis of Market Size, Share & Trends For 2019–2020 And Forecasts To 2031

[ 170 + Pages Research Report ] Genomic Biomarkers Market to surpass USD 109.94 billion by 2031 from USD 41.43 billion in 2021 at a CAGR of 13.4% in the coming years, i.e., 2021-31.

Product Overview
Genomic biomarkers are cancer detection markers that can be used at an early stage. It is a biomarker that is based on the results of a genomic test. Genomic biomarkers can be used to predict disease risk in healthy people, monitor the efficacy of disease treatments, or detect whether someone has inherited an abnormal gene that increases their risk of developing cancer. To detect genetic mutations in DNA, proteins, or metabolites, genomic biomarkers are used. The analysis of an individual's genome and proteome is included in genetic testing, which is also known as genomic testing. By examining how a person's genes respond to different drugs, the technology can detect gene changes that may increase cancer risk, guide treatment decisions, and assess response to therapy.

Market Highlights
Global Genomic Biomarkers Market is expected to project a notable CAGR of 13.4% in 2031.

The increasing prevalence of ovarian, gastric, and colorectal cancers, high demand for minimally invasive procedures, development of technologies in clinical laboratory tests, enormous developments in infrastructure for data sharing and analysis such as bioinformatics, and growing awareness about genomic biomarker-based personalized medicines are the major factors driving the growth of the genomic biomarkers market.



Global Genomic Biomarkers Market: Segments
Cardiovascular diseases segment to grow with the highest CAGR during 2021-31

Based on type, the global Genomic Biomarkers Market is fragmented into Oncology, Cardiovascular diseases, Neurological diseases, Renal Disorders, and Others. Protein markers are biomarkers that aid in the diagnosis of a wide range of diseases, including cardiovascular disorders. When these protein markers come into contact with circulating antibodies, they identify molecules secreted by cells that act as antigens, causing an immune response.

Hospital segment to grow with the highest CAGR during 2021-31

Based on end-user, the global Genomic Biomarkers Market is fragmented into Hospitals, Diagnostic Centers, and Others. In hospitals, genomic biomarkers hold the largest CAGR. The primary applications of genomic biomarkers are to diagnose, treat, and monitor the effects of therapies. The majority of genomic biomarkers are used in hospitals for cancer detection and treatment. The main reason for this is that early detection can help to prevent death to a greater extent.



Market Dynamics
Drivers
Growing awareness and advancements in R&D

Growing awareness of the role of biomarkers in the diagnosis of fatal diseases such as cancer and cardiovascular disease, as well as reimbursement issues being resolved with the intervention of regulatory authorities, are expected to propel market growth shortly. The rising prevalence of chronic diseases, as well as the increased demand for minimally invasive procedures and technological advancements, will drive the genomic biomarkers market. Furthermore, advancements in R&D, data sharing infrastructure, and demand for personalized medicines will drive market growth during the forecasted period.

Increased investments and a rise in chronic diseases

An increase in technological advancement and development in clinical laboratory tests is a critical factor driving market growth, as is an increase in the cases of gastric and ovarian cancer, an increase in the demand for genomic biomarker-based medicine, and an increase in the burden of chronic diseases, among other factors driving the genomic biomarkers market. Furthermore, rising technological advancements and modernization in the healthcare sector, as well as rising demand from emerging economies, will create new opportunities for the genomic biomarkers market during the forecasted period.

Restraint
Government regulations and high costs associated with the market

The high price, complex processes associated with genomic biomarkers, as well as stringent government regulations, are impeding the global genomic biomarkers market's growth.

Global Genomic Biomarkers Market: Key Players
Qiagen
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

Almac Group
Cancer Genetics Inc
Eurofins Scientific
Thermo Fisher Scientific Inc
Aepodia SA
Epigenomics AG
US Biomarkers Inc.
Roche Diagnostics 
Other Prominent Players
Global Genomic Biomarkers Market: Regions
Global Genomic Biomarkers Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Growth in North America's developed markets is primarily driven by the high adoption of advanced technologies, an increase in the number of research studies for the discovery and development of novel biomarkers, the presence of a large number of pharmaceutical companies, rising funding and investments from public and private organizations, and an increase in the use of biomarkers in patient stratification and the drug development process.



Global Genomic Biomarkers Market is further segmented by region into:

North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – the United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
the Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA
Global Genomic Biomarkers Market report also contains analysis on:
Genomic Biomarkers Market Segments:

By Type 
Oncology
Cardiovascular diseases
Neurological diseases
Renal Disorders
Others
By End-user 
Hospitals
Diagnostic center
Others
Genomic Biomarkers Market Dynamics 
Genomic Biomarkers Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Genomic Biomarkers Market Report Scope and Segmentation
Report AttributeDetails
The market size value in 2021USD 41.43 billion
The revenue forecast in 2031USD 109.94 billion
Growth RateCAGR of 13.4% from 2021 to 2031
The base year for estimation2020
Quantitative unitsRevenue in USD million and CAGR from 2021 to 2031
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments coveredType, End-User, and Region
Regional scopeNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Key companies profiledQiagen, Almac Group, Cancer Genetics Inc, Eurofins Scientific, Thermo Fisher Scientific Inc, Aepodia SA, Epigenomics AG, US Biomarkers Inc., Roche Diagnostics. and Other Prominent Players.
Table of Contents

1.Executive Summary
2.Global Genomic Biomarkers Market
2.1.Product Overview
2.2.Market Definition
2.3.Segmentation
2.4.Assumptions and Acronyms
3.Research Methodology
3.1.Research Objectives
3.2.Primary Research
3.3.Secondary Research
3.4.Forecast Model
3.5.Market Size Estimation
4.Average Pricing Analysis
5.Macro-Economic Indicators
6.Market Dynamics
6.1.Growth Drivers
6.2.Restraints
6.3.Opportunity
6.4.Trends
7.Correlation & Regression Analysis
7.1.Correlation Matrix
7.2.Regression Matrix
8.Recent Development, Policies & Regulatory Landscape
9.Risk Analysis
9.1.Demand Risk Analysis
9.2.Supply Risk Analysis
10.Global Genomic Biomarkers Market Analysis
10.1.Porter Five Forces
10.1.1.Threat of New Entrants
10.1.2.Bargaining Power of Suppliers
10.1.3.Threat of Substitutes
10.1.4.Rivalry
10.2.PEST Analysis
10.2.1.Political
10.2.2.Economic
10.2.3.Social
10.2.4.Technological
11.Global Genomic Biomarkers Market
11.1.Market Size & forecast, 2020A-2031F
11.1.1.By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
11.1.2.By Volume (Million Units) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.Global Genomic Biomarkers Market: Market Segmentation
12.1.By Regions
12.1.1.North America:(U.S. and Canada), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.2.Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.3.Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.4.Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.5.the Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.By Type: Market Share (2020-2031F)
12.2.1.Oncology, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.2.Cardiovascular diseases, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.3.Neurological diseases, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.4.Renal Disorders, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.5.Others, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13.By End-user: Market Share (2020-2031F)
13.1.Hospital, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13.2.Diagnostic center, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13.3.Others, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
14.Company Profile
14.1.Qiagen
14.1.1.Company Overview
14.1.2.Company Total Revenue (Financials)
14.1.3.Market Potential
14.1.4.Global Presence
14.1.5.Key Performance Indicators
14.1.6.SWOT Analysis
14.1.7.Product Launch
14.2.Almac Group
14.3.Cancer Genetics Inc
14.4.Eurofins Scientific
14.5.Thermo Fisher Scientific Inc
14.6.Aepodia SA
14.7.Epigenomics AG
14.8.US Biomarkers Inc.
14.9.Roche Diagnostics
14.10.Other Prominent Players
14.10.1.Consultant Recommendation
14.10.2.The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Report Title: Genomic Biomarkers Market: Segmented: By Type (Oncology, Cardiovascular diseases, Neurological diseases, Renal Disorders and Others); By End user (Hospitals, Diagnostic centre and Others), And Region – Global Analysis of Market Size, Share & Trends For 2019–2020 And Forecasts To 2031


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW